Inventor · disambiguated record
Annick Goergler
Also filed as: GOERGLER ANNICK
25 granted patents·13 pending applications·73 citations·filing 2001–2025
94Inventor score
Top patents by PatentIndex Score
38 records- 0197US11584748B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Feb 21, 2023·11 cites·11 claims
- 0296US12209091B2Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancersHOFFMANN LA ROCHE·Filed 2020·Granted Jan 28, 2025·7 cites·30 claims
- 0396US11623929B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Apr 11, 2023·7 cites·20 claims
- 0495US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 0594US11254672B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Feb 22, 2022·7 cites·22 claims
- 0693US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 0793US11802131B2Glutarimides for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·4 cites·9 claims
- 0893US11787802B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·3 cites·19 claims
- 0992US12344613B2EGFR inhibitor for the treatment of cancerHOFFMANN LA ROCHE·Filed 2020·Granted Jul 1, 2025·3 cites·10 claims
- 1092US11401256B2Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·5 cites·26 claims
- 1187US12091397B2Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·1 cites·13 claims
- 1280US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 1379US12365681B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2023·Granted Jul 22, 2025·0 cites·16 claims
- 1479US12227504B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Granted Feb 18, 2025·0 cites·13 claims
- 1578US7375099B2Malonamide derivativesHOFFMANN LA ROCHE·Filed 2004·Granted May 20, 2008·13 cites·19 claims
- 1678US2025289824A1Egfr inhibitor for the treatment of cancerHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 1777US2025084055A1Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1873US11319314B2PhenoxytriazolesHOFFMANN LA ROCHE·Filed 2017·Granted May 3, 2022·1 cites·19 claims
- 1972US6482829B2Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptorHOFFMANN LA ROCHE·Filed 2001·Granted Nov 19, 2002·6 cites·211 claims
- 2072US2022135571A1Therapeutic egfr inhibitorsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2171US8586617B2Aminomethyl-4-imidazolesGALLEY GUIDO·Filed 2007·Granted Nov 19, 2013·1 cites·9 claims
- 2271US2024018156A1Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2370US2025282780A1Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2469US2024199638A1Glutarimides for medical treatmentC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2565US12479849B2EGFR inhibitors for the treatment of cancerHOFFMANN LA ROCHE·Filed 2020·Granted Nov 25, 2025·0 cites·8 claims
- 2665US2022112199A1Egfr inhibitor for medical useHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2763US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2861US8389507B22-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligandsGALLEY GUIDO·Filed 2008·Granted Mar 5, 2013·0 cites·4 claims
- 2961US8242153B24,5-dihydro-oxazol-2YL derivativesGALLEY GUIDO·Filed 2009·Granted Aug 14, 2012·0 cites·21 claims
- 3059US2010041686A14,5-dihydro-oxazol-2yl derivativesGALLEY GUIDO·Filed 2009·Application pending·0 cites
- 3158US2022315591A1New egfr inhibitorsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3256US2024002390A1New indazole acetylene derivativesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3354US2024018154A1New indazole derivativesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3447US2012165294A14,5-dihydro-oxazol-2yl derivativesGALLEY GUIDO·Filed 2012·Application pending·0 cites
- 3546US8729113B24,5-dihydro-oxazol-2yl derivativesGALLEY GUIDO·Filed 2011·Granted May 20, 2014·0 cites·22 claims
- 3643US9181230B2Morpholine compounds and uses thereofHOFFMANN LA ROCHE·Filed 2013·Granted Nov 10, 2015·0 cites·21 claims
- 3740US6452001B2Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formationHOFFMANN LA ROCHE·Filed 2001·Granted Sep 17, 2002·0 cites·61 claims
- 3837US9957261B26-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivativesHOFFMANN LA ROCHE·Filed 2017·Granted May 1, 2018·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Annick Goergler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →